Zacks Investment Research Lowers Neos Therapeutics Inc. (NEOS) to Sell
Neos Therapeutics Inc. (NASDAQ:NEOS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, BMO Capital Markets reissued a “buy” rating and set a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, September 20th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Neos Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.75.
Neos Therapeutics (NASDAQ:NEOS) opened at 6.88 on Wednesday. The company’s 50 day moving average is $7.07 and its 200-day moving average is $8.68. The stock’s market cap is $110.56 million. Neos Therapeutics has a 1-year low of $6.33 and a 1-year high of $19.29.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative net margin of 968.81% and a negative return on equity of 80.10%. The firm had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $1.48 million. Equities research analysts forecast that Neos Therapeutics will post ($5.39) earnings per share for the current fiscal year.
In related news, CFO Richard I. Eisenstadt purchased 3,710 shares of the business’s stock in a transaction on Thursday, August 25th. The shares were acquired at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the purchase, the chief financial officer now owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.85% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of NEOS. Bridgeway Capital Management Inc. bought a new position in shares of Neos Therapeutics during the second quarter worth about $603,000. State Street Corp raised its position in shares of Neos Therapeutics by 61.2% in the second quarter. State Street Corp now owns 104,530 shares of the company’s stock worth $972,000 after buying an additional 39,705 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock worth $126,000 after buying an additional 1,233 shares during the last quarter. Perceptive Advisors LLC raised its position in shares of Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock worth $4,611,000 after buying an additional 526,876 shares during the last quarter. Finally, Teachers Advisors Inc. raised its position in shares of Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock worth $203,000 after buying an additional 16,296 shares during the last quarter. Institutional investors and hedge funds own 37.73% of the company’s stock.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.